siRNA, Anti-HLA-DRA, 2'-F/2'-OMe/2'-MOE/LNA/Ribo/Backbone-modified(CAT#: SIRGT11042WQ-2OMe)
The product SIRGT11042WQ-2OMe is a type of small interfering RNA (siRNA) that targets HLA-DRA gene and regulates the expression of gene. The siRNA interferes with the expression of HLA-DRA gene with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation. The siRNA is designed with 2ʹ-O-methyl (2'-OMe) modification to provide increased stability, increased specificity and reduced immunogenicity. It has potential applications in RNA interference (RNAi) and gene therapy development.
| Specifications | |
|---|---|
| NCBI RefSeq | NM_019111.4 |
| Alternative Names | HLA-DRA1 |
| Related Diseases | Graham-Little-Piccardi-Lassueur Syndrome, Heart Lymphoma |
| Purification | HPLC |
| Sub Cat | Target | Species | Modification | Scale | |
|---|---|---|---|---|---|
| SIRGT12042WQ-2F | HLA-DRA | Human | 2ʹ-deoxy-2ʹ-fluoro (2'-F) | ||
| SIRGT13042WQ-2MOE | HLA-DRA | Human | 2'-O-methoxyethyl (2'-MOE) | ||
| SIRGT14042WQ-LNA | HLA-DRA | Human | Locked Nucleic Acid (LNA) | ||
| SIRGT11042WQ-RB | HLA-DRA | Human | Ribo-modified | ||
| SIRGT12042WQ-BB | HLA-DRA | Human | Backbone-modified |